title: Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study.
abstract: BACKGROUND
  Ezetimibe has shown efficacy in the therapy of hypercholesterolemia in renal transplant patients. This is the first study investigating the effect of ezetimibe on renal function in kidney transplant recipients.
  
  
  METHODS
  Fifty-six patients with statin-resistant hypercholesterolemia (total cholesterol >200 mg/dl) after renal transplantation received additional ezetimibe therapy (10 mg/day) for 12 months. A group receiving statin therapy (n=28) served as controls in this prospective study.
  
  
  RESULTS
  Total cholesterol and LDL cholesterol concentrations decreased significantly in the ezetimibe-treated patients but remained stable in the control group (delta total cholesterol: -24+/-49 mg/dl vs 19+/-49 mg/dl, P<0.01; delta LDL: -30+/-39 mg/dl vs -3+/-31 mg/dl, P<0.01). Mean creatinine clearance remained stable in ezetimibe-treated patients but decreased significantly in control group (delta Cockcroft-Gault: 0.9+/-7.3 ml/min vs - 4.8+/-12.8 ml/min, P=0.025; delta Modification of Diet in Renal Disease: -0.4+/-6.2 ml/min/1.73 m(2) vs 4.7+/-8.8 ml/min/1.73 m(2), P=0.033).
  
  
  CONCLUSIONS
  The data of our prospective case-control study suggest that ezetimibe appears to ameliorate the decline of renal function after renal transplantation.
authors.affiliation: Department of Nephrology & Hypertension, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, D-45122 Essen, Germany.
authors.forename: Tobias R
authors.initials: TR
authors.lastname: Türk
authors.forename: Eva
authors.initials: E
authors.lastname: Voropaeva
authors.forename: Matthias
authors.initials: M
authors.lastname: Kohnle
authors.forename: Jens
authors.initials: J
authors.lastname: Nürnberger
authors.forename: Thomas
authors.initials: T
authors.lastname: Philipp
authors.forename: Andreas
authors.initials: A
authors.lastname: Kribben
authors.forename: Uwe
authors.initials: U
authors.lastname: Heemann
authors.forename: Oliver
authors.initials: O
authors.lastname: Witzke
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use*; D016022:Case-Control Studies; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D016030:Kidney Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011183:Postoperative Complications / Q000188:drug therapy*; D011446:Prospective Studies
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D000069438:Ezetimibe